OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease
Sponsor: Canadian Cancer Trials Group
Listed as NCT00036647, this PHASE3 trial focuses on Carcinoma, Non-small-cell Lung and remains completed. Sponsored by Canadian Cancer Trials Group, it has been updated 8 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jan 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Canadian Cancer Trials Group
- OSI Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Afula, Israel , Athens, Greece , Auckland, New Zealand , Bangkok, Thailand , Barrie, Canada , Belo Horizonte, Brazil , Berlin, Germany , Bloemfontein, South Africa , Bucharest, Romania , Buenos Aires, Argentina and 68 more locations